William E. Duke - May 23, 2023 Form 4 Insider Report for Apexigen, Inc. (APGN)

Role
Chief Financial Officer
Signature
/s/ Francis Sarena, by power of attorney
Stock symbol
APGN
Transactions as of
May 23, 2023
Transactions value $
-$6,904
Form type
4
Date filed
5/25/2023, 04:21 PM
Previous filing
Dec 19, 2022
Next filing
Jun 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APGN Common Stock Award $0 +150K +572.91% $0.00 176K May 23, 2023 Direct F1
transaction APGN Common Stock Tax liability -$6.9K -17.3K -9.8% $0.40 159K May 23, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported shares are represented by restricted stock units, or RSUs. Upon signing of the merger agreement between the Issuer and Pyxis Oncology, Inc. dated May 23, 2023, 60,000 RSUs vested. The remaining 90,000 RSUs vest on the earlier of (i) the closing of the merger or (ii) September 30, 2023.
F2 The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of RSUs.